Zenke FT - Search Results

1

A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.

Hollebecque A, Deutsch E, Massard C, Gomez-Roca C, Bahleda R, Ribrag V, Bourgier C, Lazar V, Lacroix L, Gazzah A, Varga A, de Baere T, Beier F, Kroesser S, Trang K, Zenke FT, Klevesath M, Soria JC. Hollebecque A, et al. Among authors: zenke ft. Invest New Drugs. 2013 Dec;31(6):1530-8. doi: 10.1007/s10637-013-0026-9. Invest New Drugs. 2013. PMID: 24077982 Clinical Trial.

2

The discovery and optimization of hexahydro-2H-pyrano[3,2-c]quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5.

Schiemann K, Finsinger D, Zenke F, Amendt C, Knöchel T, Bruge D, Buchstaller HP, Emde U, Stähle W, Anzali S. Schiemann K, et al. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1491-5. doi: 10.1016/j.bmcl.2010.01.110. Epub 2010 Jan 25. Bioorg Med Chem Lett. 2010. PMID: 20149654

3

Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors.

Buchstaller HP, Burgdorf L, Finsinger D, Stieber F, Sirrenberg C, Amendt C, Grell M, Zenke F, Krier M. Buchstaller HP, et al. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2264-9. doi: 10.1016/j.bmcl.2011.02.108. Epub 2011 Mar 1. Bioorg Med Chem Lett. 2011. PMID: 21420298

4

Novel reversible methionine aminopeptidase-2 (MetAP-2) inhibitors based on purine and related bicyclic templates.

Heinrich T, Buchstaller HP, Cezanne B, Rohdich F, Bomke J, Friese-Hamim M, Krier M, Knöchel T, Musil D, Leuthner B, Zenke F. Heinrich T, et al. Bioorg Med Chem Lett. 2017 Feb 1;27(3):551-556. doi: 10.1016/j.bmcl.2016.12.019. Epub 2016 Dec 8. Bioorg Med Chem Lett. 2017. PMID: 27998678

5

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.

Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, Grombacher T, Wilm C, Fuchss T, Amendt C, Vassilev LT, Blaukat A. Zenke FT, et al. Mol Cancer Ther. 2020 May;19(5):1091-1101. doi: 10.1158/1535-7163.MCT-19-0734. Epub 2020 Mar 27. Mol Cancer Ther. 2020. PMID: 32220971

6

Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.

Heinrich T, Seenisamy J, Blume B, Bomke J, Calderini M, Eckert U, Friese-Hamim M, Kohl R, Lehmann M, Leuthner B, Musil D, Rohdich F, Zenke FT. Heinrich T, et al. Among authors: zenke ft. J Med Chem. 2019 May 23;62(10):5025-5039. doi: 10.1021/acs.jmedchem.9b00041. Epub 2019 May 2. J Med Chem. 2019. PMID: 30939017

7

Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate.

Orth JD, Tang Y, Shi J, Loy CT, Amendt C, Wilm C, Zenke FT, Mitchison TJ. Orth JD, et al. Among authors: zenke ft. Mol Cancer Ther. 2008 Nov;7(11):3480-9. doi: 10.1158/1535-7163.MCT-08-0684. Epub 2008 Oct 30. Mol Cancer Ther. 2008. PMID: 18974392 Free PMC article.

8

Identification of Methionine Aminopeptidase-2 (MetAP-2) Inhibitor M8891: A Clinical Compound for the Treatment of Cancer.

Heinrich T, Seenisamy J, Becker F, Blume B, Bomke J, Dietz M, Eckert U, Friese-Hamim M, Gunera J, Hansen K, Leuthner B, Musil D, Pfalzgraf J, Rohdich F, Siegl C, Spuck D, Wegener A, Zenke FT. Heinrich T, et al. Among authors: zenke ft. J Med Chem. 2019 Dec 26;62(24):11119-11134. doi: 10.1021/acs.jmedchem.9b01070. Epub 2019 Dec 3. J Med Chem. 2019. PMID: 31725285

9

A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases.

Pöhler R, Krahn JH, van den Boom J, Dobrynin G, Kaschani F, Eggenweiler HM, Zenke FT, Kaiser M, Meyer H. Pöhler R, et al. Among authors: zenke ft. Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580. doi: 10.1002/anie.201711429. Epub 2018 Jan 15. Angew Chem Int Ed Engl. 2018. PMID: 29271116

10

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies.

Zimmermann A, Zenke FT, Chiu LY, Dahmen H, Pehl U, Fuchss T, Grombacher T, Blume B, Vassilev LT, Blaukat A. Zimmermann A, et al. Among authors: zenke ft. Mol Cancer Ther. 2022 Jun 1;21(6):859-870. doi: 10.1158/1535-7163.MCT-21-0934. Mol Cancer Ther. 2022. PMID: 35405736 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters